Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM)
tCGM Biosensor in Type 1 and Type 2 Diabetic Patients


    


    
</pre>
<p>FRANKLIN, Mass., <chron>Nov. 4</chron> /CNW/ -- Echo Therapeutics, Inc. (OTC Bulletin Board:   ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery announced today that it has initiated a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes.  The purpose of the study is to test the performance of its new one-piece, cost-effective and easy-to-use biosensor.  The Company expects to complete and announce the results of the study in the fourth quarter of 2009.</p>
<p/>
<p>"We are extremely pleased to take this next step forward in the development work on our one piece biosensor, a critical component of Symphony, our needle-free, continuous glucose monitoring technology," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "As we described previously, this next generation biosensor introduces new materials and a more effective geometrical construction designed to be one-piece and replaces the prior prototype two-piece biosensor used in earlier clinical trials. We believe that this biosensor will demonstrate improved performance and reliability and we look forward to confirming this in this clinical trial in Type 1 and Type 2 diabetics."</p>
<p/>
<p>Echo's pilot clinical study will enroll patients with diabetes (either Type 1 or Type 2) and will compare data obtained from its Symphony tCGM System with the "gold standard" YSI Glucose Analyzer.  The study will collect approximately 900 data pairs to be used in the analyses.  Reference glucose measurements will be made at 15 minute intervals for 24 hours with the study data blinded to study subjects and study personnel.</p>
<pre>
    

    About Echo Therapeutics

    
</pre>
<p>Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.</p>
<pre>
    

    Cautionary Statement Regarding Forward Looking Statements

    
</pre>
<p>The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.  Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System.  These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended <chron>December 31, 2008</chron>, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.</p>
<p/>
<p> </p>
<pre>
    
    For More Information:
    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer
    (856) 429-8778


    

For further information: For further information: Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics, Inc., +1-856-429-8778 Web Site: http://www.sontra.com

Organization Profile

ECHO THERAPEUTICS, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890